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Abstract
Background: Enhanced recovery after surgery programs (ERAS) using thoracic epidural anesthesia and perioperative
patient conditioning with omega-3 fatty acids (n3FA), glucose control (GC) and on-demand fluid therapy, respectively,
showed beneficial effects. In the MOFA- study these components were used together in patients undergoing colon or
liver surgery. We hypothesized that the use of a perioperative MOFA program improves intestine function represented
as time to the first postoperative bowel movement in adult patients compared to standard ERAS.
Methods: After BfArM and IRB approval 100 patients were enrolled in this prospective randomized controlled trial. All
patients received ERAS therapy (control). In addition, the MOFA group received 0.2 g/kg fish oil (Omegaven®),
preoperatively, followed by a 48 h continuous infusion of 0.2 g/kg/d n3FA; and GC was kept below < 8 mmol/
L. Pre- and postoperatively energy drinks were administered.
Results: As compared to control group the MOFA concept resulted in an earlier onset of flatulence by 14 h
(46.6 ± 25.7, 32.0 ± 17.9, p = 0.030, hours, control vs. MOFA, respectively). Effects on onset of bowel movement
were not observed (74.5 ± 30.4, 66.4 ± 29.2, p = 0.163, hours, control vs. MOFA, respectively). The disease
severity (SAPS II score; p = 0.720) as well as deployment of resources (TISS 28 score, p = 0.709) did not differ
between groups. No statistic significant difference between MOFA and control group regarding inflammation,
impairment of coagulation, length of hospital stay or incidence of postoperative surgical complications were
observed.
Conclusions: The MOFA concept did not result in an improvement of intestine function or faster recovery
after elective colon or liver surgery compared to standard ERAS therapy. Omega-3 fatty acids showed no
impairment of coagulation or improved resolution of inflammation. Further trials in a larger patient collective
are needed to investigate potential beneficial effects of omega-3 fatty acids in abdominal surgery.
Trial registration: This trial was prospectively registered at the European Union Clinical Trials Register
(EuDraCT 2005–004814-33, date: 10-05-2005, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-
004814-33+).
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Background
Within the past decade enhanced recovery after surgery
(ERAS) programs were established covering a multitude
of surgical interventions. Besides others, a meta-analysis
on ERAS in different type of hepatectomy clearly showed
improved patient outcome [1]. Aside minimizing surgi-
cal stress and improving pain control one key success
factor for further developments of ERAS programs is the
increasing control of noxious circumstances such as
overwhelming metabolism [2].
Overshooting early up-regulation of host defense after
complex surgery induces severe tissue injury, potentially
culminating systemic inflammatory response with un-
favorable outcome [3, 4]. Omega-3 fatty acids (n3FA) are
capable of dampening early hyperinflammatory processes,
by changing cell to cell signal transduction as shown [5].
Later features of host defense, however, are enhanced by
n3FA without inducing hyperinflammatory states.
The n3FA have shown their efficacy in the treatment
of chronic and acute inflammatory diseases [3] due to
their pleiotropic effects on inflammatory cell signalling
pathways [6–8]. In a variety of experimental [9, 10] and
clinical studies omega-3 fatty acids attenuated hyperin-
flammatory conditions and induced faster recovery [11].
By reducing length of antibiotic therapy and hospital
stay [12], even in critically ill patients, net cost savings
are possible from the use of n3FA despite higher ex-
penditure for the prescriptions [13].
In a prospective, open label, multicenter case series in
661 patients receiving parenteral fish oil our group eval-
uated survival, length of intensive care unit (ICU) stay,
hospital stay and use of antibiotics, with respect to the
primary diagnosis and extent of organ dysfunction [12].
Compared to the subgroup receiving less than 0.05 g/kg/
d of fish oil, significantly more patients survived when
0.1–0.2 g/kg/d were administered.
Based on this data, the present study was designed to
evaluate the effectiveness of an ERAS program supple-
mented with a priming dose of fish oil in the preopera-
tive evening and a 48 h continuous infusion of 0.2 g/kg/d
(so called ‘Metabolic Optimized FAst track concept’
[MOFA]) starting at the time of inducing anesthesia in
patients undergoing elective hepatic and colon surgery.
We hypothesized that the use of a perioperative MOFA
program improves intestine function represented as time
to the first postoperative bowel movement in adult
undergoing elective colon or hepatic surgery compared to
controls without MOFA. Second, we hypothesized that
the use of a perioperative MOFA program results in faster
postoperative recovery represented by lower Simplified
Acute Physiology Score (SAPS II) [14] as well as Simpli-
fied Therapeutic Scoring System values (TISS 28) [15] in
adult patients undergoing elective colon or hepatic surgery
compared to controls without MOFA.
Methods
The present prospective, single blind, mono-center, ran-
domized controlled trial was approved by the competent
authorities, Bundesinstitut für Arzneimittelsicherheit und
Medizinprodukte (BfArM, GZ 61–3910-4,031,476), and
Institutional Review Board of the Technische Universität
Dresden (AZ 193112005), as well as registered at
European Union Drug Review Agency Clinical Trials
(EuDraCT 2005–004814-33). The manuscript is reported
according to the CONSORT guidelines [16].
Patients and randomization
Adult patients (18 < age > 85 years) undergoing elective
colon (tumor or diverticulosis surgery) or liver surgery
(liver tumors independent from dignity without biliodi-
gestive anastomosis) in the Universtiy Hospital Carl
Gustav Carus (at the Technische Universität Dresden,
Dresden, Germany) were eligible for the trial. Exclusion
criteria were summarized in Additional file 1: Table S1.
Convenience sampling was used as recruiting strategy
and subjects were included over a three year period. Pa-
tients were randomized in blocks of four generated by a
computer program either to standard ERAS (control) or
MOFA group. To achieve homogeneity between groups
an a priori stratification of the randomization was per-
formed according to three strata: surgical procedure
(colon or liver), body mass index (BMI, < 30 or ≥ 30) and
perioperative risk classified as low or high, if one of the
following factors was present: a previous abdominal op-
eration, American Society of Anesthesiology Physical
Status 3 or higher, central liver surgery, liver tumor > 5
cm. Group allocation was concealed in sequentially
numbered opaque closed envelopes.
Experimental protocol
Detailed interventions are described in Additional file 1:
Table S2. A time course of intervention is depicted in
Fig. 1.
Preoperative care, anesthetic regimen and surgery
After enrollment in the trial baseline values were taken
and patients were randomized to control or MOFA
group. All patients received a standard ERAS protocol
with enhanced physiotherapy, short or no postoperative
ICU stay and planned discharge on the forth postopera-
tive day. In addition, the MOFA group received a prim-
ing dose of 100 ml Omegaven® 10% (Fresenius Kabi AG,
Bad Homburg, Germany) on the evening before surgery.
Two hours before the induction of anesthesia continu-
ous infusion of Omegaven® 10% with 0.083 ml/kg/h (0.2
g/kg/d) for 48 h was started and a high caloric energy
drink (ProvideXtra® Drink 200 ml, Fresenius Kabi AG,
Bad Homburg, Germany) administered orally in the
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MOFA group. All patients received general anesthesia
with propofol/sufentanil for induction and volatile anes-
thetics in combination with sufentanil and thoracic epi-
dural anesthesia (TEA) for maintenance. The choice of
the volatile anesthetic and the neuromuscular blocking
agent for continuous muscle relaxation was on the dis-
cretion of the anesthesiologist. Co-priming with 500 ml
colloid solution before the first injection of local
anesthetic for the epidural anesthesia was performed in
the MOFA group. An arterial line as well as a central
venous catheter were placed in all patients. Intraopera-
tive fluid was restricted to 4 ml/kg/h. Surgery was car-
ried out by a predefined experienced team of specialists
in abdominal surgery. All patients who underwent liver
surgery received a transverse upper abdomen laparot-
omy and in case of colon surgery a median laparotomy
or laparoscopic approach as appropriate. Patients were
extubated directly after the end of surgery. Intraopera-
tive blood glucose level was kept below 8mmol/L.
Postoperative management
Patients who received colon surgery and basic liver sur-
gery were transferred to the post anesthesia care unit
and then to normal ward. Subjects undergoing more
complex liver surgery were allocated to the ICU directly
after end of anesthesia. On the day of surgery oral fluids
were administered postoperatively from 2 h on. In the
MOFA group the high caloric energy drink was given
and Omegaven® 10% infusion was stopped at 2nd post-
operative day. Patients were endorsed to drink > 1500ml
per day. A fast progress to solid food was intended.
Physical mobilization and breathing exercises started 5 h
after the end of surgery and were continued until dis-
charge. Infusion was limited to 500 ml per day. TEA was
continued as patient controlled analgesia until the 2nd
postoperative day and removed together with the central
venous line. Blood sugar level was aimed to be kept be-
tween 4mmol/L and 8mmol/L in the MOFA group and
between 4mmol/L and 10 mmol/L in the control group
during the first three postoperative days (Additional file
1: Table S3). Discharge was aimed from the fourth post-
operative day on.
Safety thresholds
Participation in the trial was terminated at any time point,
if one of the following dropout criteria was present: request
of the patient, therapy refractory bowel paralysis, allergic re-
action to study medication, onset of contraindications
against enteral nutrition, development of septic shock and
violation of safety parameters. Safety parameters to avoid
bleeding complications were measured daily during the first
three postoperative days. The following safety thresholds
were defined: hemoglobin > 4.5mmol/L, platelets > 50 Gpt/
L, prothrombin time (PT) > 50%, activated partial thrombo-
plastin time (aPTT) < 60 s. If a safety threshold was violated,
Omegaven® infusion was stopped and reasons for violation
were investigated.
Measurements and data collection
Daily visits throughout the study period were performed.
Investigators collecting data were not blinded to groups.
Patients were unaware of group allocation but blinding
could be easily broken. Preoperative baseline data in-
cluded physical examination, basic monitoring (blood
pressure, peripheral oxygen saturation) and laboratory
parameters (complete blood count, aPPT, PT, antithrom-
bin, fibrinogen, blood urea nitrogen, creatinine, c-reactive
protein (CRP), procalcitonin (PCT), tumor necrosis fac-
tor-alpha (TNF-α), interleukin 6 (IL-6) and 10 (IL-10),
blood sugar, lactate). These measurements were repeated
Fig. 1 Time course of interventions After enrollment in the trial baseline values were taken and patients were randomized to control or MOFA
group. All patients received a standard ERAS protocol with enhanced physiotherapy, short or no postoperative intensive care unit stay and planned
discharge on the forth postoperative day. In addition, the MOFA group received a priming dose of 100ml omegaven 10% on the evening before
surgery. Two hours before the induction of anesthesia continuous infusion of omegaven 10% with 0.083ml/kg/h (0.2 g/kg/d) for 48 h was started and
a high caloric energy drink administered orally in the MOFA group. ERAS: enhanced recovery after surgery concept, MOFA: metabolic optimized fast
track concept, TEA: thoracic epidural analgesia, BL: baseline, D-1: preoperative day, D0: day of surgery, D1-D4: postoperative day 1–4, respectively
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until the third postoperative day. Data from the medical
record were extracted daily. The presence of flatulence
and/or bowel movement was documented during the first
postoperative days. The TISS 28 and SAPS II scores were
calculated daily.
Statistics
All calculations were performed using SPSS (IBM SPSS Sta-
tistics Vers. 23.0.0.0, IBM Deutschland GmbH, Ehningen,
Germany). Graphs were computed with GraphPad Prism
(Vers. 6.01, GraphPad Software Inc., La Jolla, CA, USA).
Sample size was calculated based on an internal database
consisting of 291 patients undergoing colon surgery, where
the time to the first bowel movement was 3.25 ± 1.7 days.
With an assumption of a two-sided α of 0.05 and a statis-
tical power of 0.80, 47 patients per group were calculated
to be necessary to accelerate the onset of bowel movement
(primary endpoint) by one day. To compensate for drop-
outs, a sample size of 50 per group was projected. Distribu-
tion of the data was assessed visually using Q-Q-Plot.
Patient data were analyzed as intention to treat. No as-
sumption for missing data was done. Values are given as
median, 25% percentile, 75% percentile, minimum and
maximum; mean ± standard deviation or absolute number
(percentage); as appropriate. The analysis of the primary
endpoint was performed with log rank test and cox regres-
sion. A two-sided Student’s t-test or Mann-Whitney U test
were used as appropriate for binary outcomes. Statistical
significance between groups for repeated measures as well
as time effect and time vs. group effect were calculated with
a general linear model using the respective baseline data as
covariate. Statistical significance was considered to be at
two-sided p < 0.05.
Results
The consort diagram is depicted in Fig. 2. Out of 347
screened patients, 100 consecutive patients were enrolled
in the trial. Various dropouts, mainly caused by more
complex resections than planned due to intraoperative
tumor spread, resulted in 79 patients (n = 37 control, n =
42 MOFA group) with available follow up data. Baseline
characteristics are summarized in Table 1.
Bowel function
Postoperative bowel function is shown in Table 2. With
the MOFA concept an earlier onset of discharge of gas
by 14 h (46.6 ± 25.7, 32.0 ± 17.9, p = 0.030, hours, control
vs. MOFA, respectively) was detected. However, there
was no statistic significant difference in bowel movement
(74.5 ± 30.4, 66.4 ± 29.2, p = 0.163, hours, control vs.
MOFA, respectively) or the administration of agents for
bowel stimulation.
Recovery after surgery
As shown in Fig. 3, no statistic significant difference in
disease severity, represented by the SAPS II score was
observed between control and MOFA group (p = 0.720).
The deployment of resources measured by the TISS 28
score did not differ between groups (Fig. 3). Duration of
anesthesia and surgery, intraoperative blood loss, overall
amount of administered crystalloids and transfusions
were comparable between groups (Table 3). Patients
undergoing liver surgery received more crystalloids in
the control group compared to MOFA group. Postoper-
ative surgical complications were higher in the control
group causing trial dropouts mainly due to insufficiency
of anastomosis with consecutive reoperation and impos-
sible enteral nutrition (Table 3). There were no statistic
significant differences, neither in length of ICU nor in
length of hospital stay (Table 3). There was one in-hos-
pital death in the control group due to myocardial in-
farction with consecutive multi-organ failure after
cardiac arrest.
Hemodynamics, clinical chemistry and metabolic data
Hemodynamics are summarized in Additional file 1:
Table S4. No difference between groups were de-
tected. The blood sugar level was kept below 10
mmol/L in the control group and below 8 mmol/L in
the MOFA group (Additional file 1: Figure S1) result-
ing in a higher insulin administration in the MOFA
group (Additional file 1: Table S5). There was no dif-
ference in serum values of parameters of liver injury
and function (Additional file 1: Figure S3). Both
groups had comparable kidney function (Additional
file 1: Table S6).
Inflammation
Pro- and anti-inflammatory cytokines as well as clinical
relevant parameters of inflammation are depicted in
Additional file 1: Figure S4. No difference between
groups in CRP, PCT, IL-6, TNF-α or IL-10 were ob-
served in the MOFA group compared to control.
Safety thresholds and investigational drug related
adverse events
Coagulation parameters were comparable between
groups (Additional file 1: Figure S2) and intraopera-
tive blood loss was comparable. Severe postoperative
bleeding complications did not occur in the MOFA
group compared to control measured on need for
transfusion (Table 3) and hemoglobin and hematocrit
levels were comparable between groups (Additional
file 1: Table S6). However, in one patient, who under-
went liver surgery with unplanned high intraoperative
blood loss, Omegaven® was stopped precautiously on
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the first postoperative day by the treating intensivist
although safety thresholds were not violated.
Discussion
The current trial is an independent investigator-initiated
trial focusing on perioperative effects of the MOFA pro-
gram. The trial was controlled and the interventions
were simple and feasible, which improves external valid-
ity. The research question is highly relevant considering
around 2.1 million patients treated for gastrointestinal
diseases in Germany every year (according to hospital
database of the German Federal Agency for Statistics –
Statistisches Bundesamt) resulting in approximately
8500 EUR up to 11,800 EUR costs per colon procedure
and approximately 10,000 EUR up to 15,500 EUR costs
per liver procedure [17–19].
Major findings
Major findings of the present trial are
1. The MOFA concept did not result in an
improvement of intestine function represented
as time to the first postoperative bowel
movement in adult patients undergoing elective
colon or hepatic surgery compared to standard
ERAS therapy.
2. A faster recovery after surgery measured by the
SAPS II score was not observed in the MOFA
group compared to control group.
Fig. 2 Flowchart. Consecutive patients undergoing open liver or colon surgery were enrolled in the trial and randomized into ERAS and MOFA
group. During the follow up period 28 patients were lost. Finally, 79 patients were analyzed in the per protocol analysis. ERAS: enhanced recovery
after surgery concept, MOFA: metabolic optimized fast track concept, ITT: intention to treat
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3. Omegaven® did not cause statistic significant
impairment of coagulation or higher intraoperative
blood loss compared to standard ERAS therapy.
ERAS programs in abdominal surgery
Careful analgesia, early enteral feeding and early
mobilization are one of the key stones of modern fast
track surgery [20]. The ERAS programs in abdominal
surgery improve patient outcome and reduces costs [21,
22]. However, the comparability of the different ERAS
approaches were questioned [22]. In the present trial our
standard ERAS program consists of various interventions
all recommended by the ERAS Society [20]. One essen-
tial part of our standard ERAS program is epidural
anesthesia. Thoracic epidural anesthesia enhances
gastrointestinal transit and reduces postoperative pain
compared to conventional opioid analgesia [23]. The
placement of epidural catheters in patients undergoing
laparoscopic surgery might be obsolete considering risks
and benefits as well as the alternative treatment with
systemic opioids and/or local wound infiltration [24].
Furthermore, epidural anesthesia may be contraindicated
in case of anticoagulant therapy [25], whereby various
patients may be excluded from our proposed standard
ERAS or MOFA program in case of early begin of anti-
coagulant therapy especially after laparoscopic surgery.
In addition, new regional anesthetic techniques like the
transverse abdominis plane block (TAP) or the paraver-
tebral block, which are less invasive and have in case of
TAP block less contraindications regarding anticoagula-
tion showed comparable or better results with respect to
analgesic effect or complications compared to TEA [26,
27]. However, a careful analgesia without influencing
gastrointestinal transit may be a key concept independ-
ent of the type of analgesia. In addition, perioperative
blood glucose control is essential. Kotagal and colleagues
found in a retrospective cohort study in more than 40,
000 patients undergoing abdominal surgery that peri-
operative hyperglycemia is associated with more adverse
events even in patients without diabetes mellitus [28].
Table 1 Baseline characteristics
Control group (n = 50) MOFA group (n = 50)
Age [years] 61 ± 12 60 ± 19
Gender [no./%]
Female 16 (32.0) 18 (36.0)
Male 34 (68.0) 32 (64.0)
Body height [m] 1.73 ± 0.09 1.70 ± 0.09
Body weight [kg] 82.7 ± 16.2 80.5 ± 15.7
BMI [kg/m2] 27.6 ± 4.7 27.9 ± 4.2
Surgical procedure [no./%]
Colon 30 (60.0) 30 (60.0)
Liver 20 (40.0) 20 (40.0)
Surgical technique [no./%]
Laparoscopic 6 (12.0) 5 (10.0)
Open 43 (86.0) 45 (90.0)
Conversiona 1 (2.0) 0 (0.0)
ASA [no./%]
I 2 (4.0) 8 (16.0)
II 29 (58.0) 30 (60.0)
III 19 (38.0) 12 (24.0)
Preconditions
IDDM 2 (4.0) 3 (6.0)
NIDDM 6 (12.0) 4 (8.0)
Arterial hypertension 29 (58.0) 25 (50.0)
Coronary heart disease 2 (4.0) 6 (12.0)
COPD 1 (2.0) 0 (0.0)
Values are given as absolute number (percentage) or mean ± standard
deviation, as appropriate. ASA American Society of Anesthesiology physical
status, BMI Body mass index, COPD Chronic obstructive pulmonary disease,
IDDM Insulin dependent diabetes mellitus, MOFA Metabolic optimized fast
track concept, NIDDM Non-insulin dependent diabetes mellitus, a:
intraoperative conversion from laparoscopic to open abdominal surgery
Table 2 Postoperative intestinal function
Control group MOFA group P value
First bowel movement [h] 74.5 ± 30.4 [38] 66.4 ± 29.2 [43] 0.163
First discharge of gas [h] 46.6 ± 25.7 [36] 32.1 ± 17.9 [43] 0.030
Bowel sounds [h] 40.8 ± 14.6 [40] 34.4 ± 14.1 [44] 0.042
Onset of enteral nutrition [days] 0.0 (0.0, 0.0, 1.0, 5.0) [42] 0.0 (0.0, 0.0, 1.0, 3.0) [43] 0.252
Bowel stimulationa [days of onset] 2.0 (0.0, 0.0, 3.0, 6.0) [39] 2.0 (0.0, 0.0, 3.0, 5.0) [43] 0.703
Bowel stimulationa [n] 20 (51.3) [39] 22 (51.2) [43] 1.000
Values are given as mean ± standard deviation, median (minimum, 25% percentile, 75% percentile, maximum) or absolute number (percentage) as appropriate.
Number of analyzed patients can be found in brackets. Statistical significance was considered to be at two-sided p < 0.05. Differences between groups were
tested using log rank test and cox regression. Frequencies were analyzed using Fisher’s Exact test or Chi square test, as appropriate. MOFA Metabolic optimized
fast track concept, a: bowel stimulation includes pharmacological and osmotic/mechanical stimulation
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Therefore, the MOFA group received more insulin than
the control group, but without resulting in lower blood
glucose levels compared to control group. However, the
average blood sugar level was below 8mmol/L for most
of the measurement points in both groups.
Influence of omega-3 fatty acids
Host defense is one of the most complexly regulated sys-
tems within the mammalian organism. Multitudes of back
coupling mechanisms are responsible for up-regulating
the immune response and for subsequent shut down of
hostile responses during recovery. Through several posi-
tive feedback loops early host defense can induce hyperin-
flammatory states. Counterbalancing antagonistic systems
are induced with a time delay. The early phase (0–72 h) is
characterized by the predominance of pro-inflammatory
eicosanoids, cytokines (e.g. TNF-α, IL-1, IL-6, IL-8) and
the in parts overlapping later phase by the predominance
of anti-inflammatory cytokines (IL-4, IL-10, IL-13 and
transforming growth factor-β) [29, 30]. This time course
of cytokine production can differ in patients with recur-
rent septic episodes.
The addition of Omegaven® to the standard ERAS
treatment was promising due to several of beneficial im-
munomodulatory effects described in the literature.
Omegaven® is a lipid parenteral formula which contains
10 g fish oil/100ml which correspondingly has 1.25–
2.82 g eicosapentaenoic acid (EPA, 20:5 n-3) and 1.44–
3.09 g docosahexaenoic acid (DHA, 22:6 n-3) [31]. The
n-6:n-3 PUFA ratio in Omegaven® is 1:6–8.
In the recent years a couple of meta analyses in the
field of intravenous n3FA administration shed light on
their efficacy in surgical patients [32–34] as well as in
critical illness [32, 35, 36]. Significantly lower infection
rates, ICU stay, and length of hospital stay have concor-
dantly been identified in three recent meta-analyses in
surgical patients [32, 37, 38]. In this regard the post-
traumatic metabolism after gastrointestinal cancer sur-
gery was improved [4], which may in part be explained
by resolvin E1 activity [39]. This complex regulation is
conferred by reduced release of pro-inflammatory ara-
chidonic acid-derivatives and platlet-activating factor,
and, on the other hand, by the amplification of anti-in-
flammatory EPA-derivatives, which lower the formation
of cytokines such as TNF-α and IL-1 [40], without inhi-
biting phagocytosis, burst activity, or bactericidal activity
[41]. The observed modulation of inflammation by
n3FA, thus, cannot unequivocally be assigned to the
pro- or anti-inflammatory side. While early pro- inflam-
matory eicosanoids are down- regulated, later on, cellu-
lar host defense mechanisms are augmented.
Besides the physiological rationale and experience
from small clinical trials, Omegaven® failed to improve
postoperative intestinal function, inflammation and
recovery from surgery in the present trial. We noticed
neither an aggravation nor depression of immune func-
tion represented by cytokine levels and clinical relevant
inflammatory parameters. In our opinion, four different
reasons could explain those findings: 1) the trial was
underpowered; 2) the dosage of Omegaven® was too low;
3) the start of Omegaven® was too late or the duration of
administration was too short and 4) there is no clinical
favourable effect of Omegaven® regarding intestinal func-
tion, inflammation or recovery after surgery.
Several factors may contribute to low power in the
present trial. The estimated compensation of 6% for
dropouts by three subjects per group was too low. Both
the ERAS and MOFA program consists of various inter-
ventions, which may lead to patient inconvenience and
therefore denying consent during the trial. In addition,
the time of first bowel movement after colon surgery,
which was used for sample size calculation may be dif-
ferent between from those after receiving liver surgery.
However, since a statistic significant difference in the
onset of flatulence was observed in the MOFA group,
the authors consider the statistical power as main reason
for failing the primary endpoint.
Finding the correct dosage of study medication in clin-
ical trials is challenging. Heller et al. conducted a large
Fig. 3 TISS 28 and SAPS II score. Values are given as mean ± standard
deviation. Statistical significance was considered to be at two-sided p <
0.05. Differences between groups, as well as time and time vs. group
effect were tested using a general linear model with the respective
baseline value as covariate. a: linear effect, b: quadratic effect, BL: baseline,
EoS: Evening of surgery, D1-D5:postoperative day 1–5, respectively. SAPS:
Simplified Acute Physiology Score, TISS: Simplified Therapeutic Scoring
System, MOFA: metabolic optimized fast track concept
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Table 3 Duration of Surgery, Anesthesia, ICU and hospital stay, Complications of surgery
Control group MOFA group P value
Duration of surgery
[min]
All 190 (92,157, 265, 529) [50] 215 (89, 158, 310, 560) [50] 0.425
Colon 175 (92, 150, 203, 293) [30] 206 (89, 153, 268, 482) [30] 0.240
Liver 235 (130, 169, 397, 528) [20] 221 (92, 166, 336, 560) [20] 0.654
Duration of anesthesia
[min]
All 276 (180, 239, 355, 620) [50] 300 (176, 245, 418,632) [50] 0.491
Colon 262 (180, 238, 309, 390) [30] 289 (187, 243, 361, 570) [30] 0.578
Liver 335 (196, 237, 537, 620) [20] 323 (176, 245, 465, 632) [20] 0.186
Intraoperative blood loss
[ml]
All 175 (0, 30, 1025, 3000) [50] 400 (0, 30, 950, 3000) [49] 0.775
Colon 50 (0, 30, 200, 1150) [30] 30 (0, 20, 100, 3000) [29] 0.399
Liver 1100 (100, 613, 1438, 3000) [20] 950 (50, 525, 1950, 2820) [20] 0.909
Need for transfusionb [no]
All 10 (20.0) [50] 6 (12.0) [50] 0.414
Colon 2 (6.7) [30] 1 (3.3) [30] 1.000
Liver 8 (40.0) [20] 5 (25.0) [20] 0.501
Transfusion products
PRBC [units] 4.0 (2.0, 2.5, 5.0, 8.0) [9] 2.5 (1.0, 2.0, 4.0, 6.0) [8] 0.288
FFP [units] 4.0 (2.0, 2.0, 5.25, 9.0) [6] 3.0 (2.0,2.0, 4.0, 4.0) [4] n.a.
Cumulative fluid therapy
Crystalloids [ml]
All 2500 (500, 1375, 3500, 5900) [50] 1750 (0, 1100, 2500, 6500) [49] 0.054
Colon 1500 (500, 1000, 2500, 5500) [30] 1500 (0, 1000, 2250, 6500) [29] 0.758
Liver 3500 (2000, 3000, 4000, 5900) [20] 2263 (0, 1500, 3500, 5300) [20] 0.004
Colloids [ml]
All 500 (0, 500, 1500, 2500) [50] 1000 (0, 500, 1500, 3000) [49] 0.043
Colon 500 (0, 0, 1000, 2000) [30] 500 (0, 500, 1000, 3000) [29] 0.005
Liver 1500 (500, 500, 1500, 2500) [20] 1500 (0, 500, 2000, 3000) [20] 0.504
Hospital length of stay [days]
All 8.0 (6.0, 8.0, 9.0, 20.0) [37] 8.0 (6.0, 8.0, 9.0, 20.0) [43] 0.466
Colon 8.0 (6.0, 7.0, 10.0, 30.0) [23] 8.0 (6.0, 7.0, 9.0, 12.0) [27] 0.651
Liver 8.0 (6.0, 8.0, 9.0, 20.0) [14] 9.0 (7.0, 8.8, 10.3, 13.0) [16] 0.860
ICU length of stay [hours]
All 34 (21, 23, 49, 67) [14] 27 (12, 20, 45, 80) [15] 0.237
Colon 49 [1] 30 (12, 13, 43, 44) [4] n.a.
Liver 25 (21, 22, 49, 67) [13] 27 (18, 21, 45, 88) [11] 0.558
Postoperative surgical complicationsa [no.]
Bleeding 0 (0.0) [50] 1 (2.0) [50] 1.000
Insufficiency of 4 (8.0) [50] 0 (0.0) [50] 0.118
anastomosis
Wound infection 3 (6.0) [50] 0 (0.0) [50] 0.242
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observational study of intravenous fish oils in 661 pa-
tients from 82 German hospitals [12]. Doses between
0.05–0.2 g/kg/day of fish oil were given to mixed hos-
pital patients for at least 3 days. An average of 0.11 g/kg/
day [range 0.005–0.426 g/kg/day] was administered for
an average of 8.7 ± 7.5 days. Fish oil administration sig-
nificantly lowered hospital mortality from 18.9 to 12% as
predicted by SAPS II scores. Fish oil doses > 0.05 g/kg/
day significantly decreased length of ICU and hospital
stay. Doses between 0.1–0.2 g/kg/day was associated
with significantly higher survival rates compared to
doses < 0.05 g/kg/day. Finally, a lowered antibiotic de-
mand of 26% was observed in patients receiving 0.15–
0.2 g/kg/day of fish oil. Based on this trial we opted for
Omegaven® dosage. Wang et al. administered up to 10 g/
day by giving 0.15–0.2 g/kg/day of fish oil from Omega-
ven® in 40 adult patients with severe acute pancreatitis
[42]. Clinical parameters were measured on day 6, the
following day after the intervention. In the fish oil
treated group, EPA was significantly higher in plasma
membranes, CRP concentrations were lower and oxy-
genation index were higher compared to control. How-
ever, an optimal dose finding trial should be performed
before conducting future clinical trials involving intra-
venous Omegaven®.
The optimal time point for beginning, the duration
as well as the route of administration of n3FA is still
crucial. As shown by Brower et al., the intestinal re-
sorption of n3FA is not sufficient in all patients dur-
ing systemic inflammation [43]. Therefore, an
intravenous administration is favorable. The optimal
start and duration of supplementation with n3FA was
chosen to cover the peak of inflammatory response.
However, an orally supplementation in a longer
period before surgery may enhance beneficial effects
of n3FA. Furthermore, recent orally available n3FA
formulas consisting of monoglycerids attached with
EPA (EPA/DHA ratio 10:1) and less fishy taste may
be opted for oral supplementation before and after
surgery [44].
Recent randomized controlled trials showed no effect
on mortality in critical ill or cancer patients undergoing
elective surgery [45, 46]. These findings are supported
by metaanalysis, which showed no benefit on mortality
or infectious complications [36]. However, there is
the possibility that n3FA do not have an effect on in-
testinal function, resolution of inflammation or recov-
ery after surgery in the currently investigated patient
collective. Nevertheless, in awareness that the present
trial is underpowered a generalization of the results
cannot be made.
Safety of Omegaven®
The anti-thrombotic and anti-atherogenic effects of
fish oil have raised potential safety concerns due to
decreased blood viscosity, which could decrease blood
clotting [47]. To date, negative clinical data is sparse
for prolonged bleeding times for fish oil alone, or in
combination with blood thinners [48–50] with the
exception of some isolated case reports on possible
interactions between warfarin and/or trazodone and/
or aspirin with oral fish oil [51–54]. Fish oil supple-
mentation has shown to be safe in various RCTs in
conjunction with and without anti-coagulant therapy.
In the GISSI multi-center trial, no negative blood
thinning interactions were reported in over 10,000
post-myocardial patients that consumed around 1 g/
day DHA + EPA from fish oil in combination with
blood thinning agents for 3–5 years [55]. In high risk
surgical patients undergoing major vascular surgeries,
femoral oral artery puncture or percutaneous translu-
minar coronary angioplasty, Harris reported on 20
studies which included over 4300 subjects that sup-
plemented between 1 and 21 g/day fish oil concomi-
tantly with blood-thinning medications in subjects
[48]. Of these, 5 bleeding complications were reported
and no clinically relevant extended bleeding times
were documented.
Statistical significant undesirable effects of n3FA on
coagulation or bleeding disorders did not occur in the
Table 3 Duration of Surgery, Anesthesia, ICU and hospital stay, Complications of surgery (Continued)
Control group MOFA group P value
Non-infective wound 1 (2.0) [50] 1 (2.0) [50] 1.000
complication
Biliary fistula 0 (0.0) [50] 0 (0.0) [50] n.a.
Reoperation 4 (8.0) [50] 0 (0.0) [50] 0.118
other 2 (4.0) [50] 2 (4.0) [50] 1.000
In-hospital death [no.] 1 (2.0) [50] 0 (0.0) [50] 1.000
Values are given as mean ± standard deviation, median (minimum, 25% percentile, 75% percentile, maximum) or absolute number (percentage) as appropriate.
Number of analyzed patients can be found in brackets. Statistical significance was considered to be at two-sided p < 0.05. Differences between groups were
tested using a Student’s t-test or Mann-Whitney U test as appropriate. Frequencies were analyzed using Chi-square or Fisher’s Exact test, as appropriate. FFP Fresh
frozen plasma, ICU Intensive care unit, MOFA Metabolic optimized fast track concept, PRBC packed red blood cells. a: Postoperative surgical complications are
provided during whole hospital stay or until dropout. b: need for transfusion is given during whole hospital stay or until dropout
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present trial. However, because the present trial is
underpowered, further trials are needed to investigate
the safety of Omegaven® regarding impairment of
coagulation.
Limitations
The present trial has several limitations. First, the trial
was an open label trial, which may have and severe im-
pact on outcome [56]. Blinding of outcome assessors
and patients via a double dummy design with sham infu-
sion of crystalloid infusion would have improved drastic-
ally trial costs for camouflaging study medication.
Second, the trial is underpowered due to the high rate of
dropouts in both groups as discussed before. Third, liver
and colon surgery may be too heterogeneous since
higher blood loss and transfusion are more likely to
occur in liver surgery. We opted for a stratified
randomization strategy, which enrolled an equal number
of patients with liver resection in both groups which en-
hanced comparability and improved external validity of
the trial. Forth, only a few patients received laparoscopic
surgery in our center, whereby the use of laparoscopic
techniques is improving for simple and also complex
liver and colon surgery. In addition, less surgical trauma
may be caused by laparoscopic techniques resulting in
moderated inflammatory response confounding the
study results. Fifth, the placement of epidural anesthesia
in patients undergoing laparoscopic surgery might be
obsolete considering risks and benefits as well as the al-
ternative treatment with systemic opioids and/or local
wound infiltration as mentioned before [24]. Further-
more, epidural anesthesia may be contraindicated in case
of anticoagulant therapy [25], whereby various patients
may be excluded from our proposed standard ERAS or
MOFA program in case of early begin of anticoagulant
therapy especially after laparoscopic surgery. However,
considering a trial design without obligate TEA, an im-
balance between groups with different number of TEA
would be a clear confounder, due to enhanced bowel
movement and shorter hospital stay by TEA after ab-
dominal surgery [44]. Sixth, the evaluation of safety
thresholds might be difficult in case of large blood loss
caused by surgery.
Implications for further studies
Further trials investigating the influence of n3FA in a larger
patient collective undergoing abdominal surgery are war-
ranted. Such a trial should be randomized controlled with a
double dummy design, focusing on the effects of omega-3
fatty acids in patients undergoing open abdominal surgery.
An optimal dose finding trial as well as the optimal time
point for beginning of the Omegaven® treatment is neces-
sary. A preoperative start of orally n3FA supplementation
for instance twoweeks before surgery and a longer
supplementation period of for instance 4 weeks postopera-
tively may enhance the immunomodulatory effect of n3FA.
An increase in daily dosage to 0.5 g/kg/d fish oil may result
in a clinical relevant improvement of intestinal function
and faster recovery after surgery.
Conclusions
The metabolic optimized fast track concept did not result
in an improvement of intestine function or faster recovery
after elective colon or liver surgery compared to standard
enhanced recovery after surgery program. Omega-3 fatty
acids showed no impairment of coagulation or improved
resolution of inflammation. Further trials in a larger pa-
tient collective are needed to investigate potential benefi-
cial effects of omega-3 fatty acids in abdominal surgery.
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